

1 **Characterization of a novel amastin-like surface protein (ALSP) of *Leishmania***  
2 ***donovani*, a probable lipase**

3

4 Bapi Biswas<sup>1</sup>, Bhakti Laha<sup>1</sup>, Arun Chaudhury<sup>2</sup>, Monidipa Ghosh\*<sup>1</sup>

5

6 <sup>1</sup>Department of Biotechnology, National Institute of Technology Durgapur, Durgapur-713209,  
7 India

8

9 <sup>2</sup>GIM Foundation, Little Rock 72223 USA

10

11

12 **Corresponding Author:** Monidipa Ghosh Tel: +91-9434789001; Fax: +91-343- 2754027; Email:  
13 monidipa.ghosh@bt.nitdgp.ac.in

14

15 **Word count:** 7030

**Number of figures:** 7

16 **ABSTRACT**

17 In the current study, a novel putative protein of *Leishmania donovani*, amastin-like surface  
18 protein (ALSP) has been characterized. The gene was cloned in a bacterial system and the  
19 protein was overexpressed. A polyclonal antibody was developed against the protein, which  
20 detected a 10kDa band in the *L. donovani* amastigote. ALSP mRNA was detected in *L.*  
21 *donovani* amastigote, which was not expressed in the promastigote. ALSP mRNA was  
22 unexpressed in either morphological forms of *Leishmania major*. MALDI-TOF confirmed  
23 the molecular weight of ALSP as 10 kDa. I-TASSER predicted the function of ALSP as a  
24 lipase, which we confirmed in preliminary *in vitro* experiments using amastigotes of *L.*  
25 *donovani*. ALSP has GAS amino acid sequences, which might act as the active site for its  
26 lipase activity. The selective expression of ALSP in amastigotes probably makes it important  
27 in virulence mechanisms such as survival in the phagolysosome and modulation of its  
28 membrane and other metabolic functions, necessary for parasite survival in the human host.  
29 ALSP can act as a peptide vaccine target and maybe detected in the peripheral blood or urine  
30 as a molecular biomarker of active disease in visceral leishmaniasis.

31 **Keywords:** amastin, lipase, host-parasite, *Leishmania donovani*, parasitism, lipid organelle.

32

## 33 INTRODUCTION

34 Leishmaniasis is an insect-borne global scourge caused by the protozoan parasite *Leishmania*.  
35 The morphology of different species of *Leishmania* alternates between two distinct morphs:  
36 an extracellularly located flagellated promastigote swarming in the gut of wide species of  
37 female phlebotomine sandflies and morphologically distinct intracellular located non-  
38 flagellated amastigote transmitted to the blood of the mammalian host (Leifso et al., 2007;  
39 Pulvertaft and Hoyle 1960). World Health Organization (WHO) reports that 12 million  
40 individuals are affected by leishmaniasis around the globe, among which 20,000–40,000  
41 people are decimated by the disease every year (Alvar et al., 2012). Limited drugs such as  
42 antimonials, amphotericin B and miltefosine are available to treat visceral leishmaniasis (kala  
43 azar) but they are limited in their efficacy due to toxic effects, nonspecific modes of action,  
44 increasing drug resistance and rising cost (Sundar and Agarwal, 2016). There are no vaccines  
45 as well against the parasite (Ghosh and Bandopadhyay, 2003, Zutshi et al., 2019).

46 Kinetoplast organisms like *Leishmania donovani* and other *Leishmania* species,  
47 *Trypanosoma brucei* (causing sleeping sickness) and *Trypanosoma cruzi* (causing Chagas  
48 disease) expresses a wide family of surface glycoprotein called amastins. *In-silico* prediction  
49 studies have highlighted a predicted low molecular weight analog called amastin-like surface  
50 protein (ALSP) (Gene ID: LdBPK\_301490.1) (Aslett M et al., 2010; Sengodan et al, 2014).  
51 Whether at all ALSP is related to amastin is hitherto unknown. Previous studies have shown  
52 that the immunogenicity of amastin sequences are furthest than all surface antigens of  
53 *Leishmania* in mice (Stober et al., 2006) and show intense immunogenicity with human  
54 visceral leishmaniasis (Rafati et al., 2006). A low molecular weight protein may be an  
55 efficient target for vaccine candidacy (Khan et al., 2020). Diverse amastin protein are  
56 translated in *L. donovani* amastigotes in individuals with visceral leishmaniasis (Rochette et  
57 al., 2005; de Paiva et al., 2015). Our preliminary studies of structural predictions highlighted  
58 a lipase-like role for ALSP. Some previous studies have identified lipases as a key virulence  
59 factor for the live amastigote in the host phagolysosome and coordination of complex  
60 metabolism. The lipid turnover renders the macrophage rather effete in eliminating the  
61 amastigote (Wassef et al., 1985, Bouazizi-Ben Messaoud et al., 2017, Rabhi et al., 2012).  
62 Lipases may also modulate membrane properties and tissue modelling to favor widespread  
63 dissemination, as seen in visceralization of the parasite. (O'Neal et al., 2020, Ramakrishnan et al.,  
64 2013, Biagiotti et al., 2017, Beach et al., 1979).

65 In the current study, we characterized the novel amastin-like surface protein (ALSP),  
66 including expressing its gene in a bacterial system, overexpressing the protein in vitro, testing  
67 its molecular weight and expression patterns in both the promastigote and amastigote of *L.*  
68 *donovani* and examining its predicted function as a lipase.

## 69 **MATERIALS AND METHODS**

### 70 *Culture of cells and parasites*

71 Promastigotes of *L. donovani* (AG83) were maintained at 23 °C in Medium199 (M199), with  
72 10% FBS (Fetal Bovine Serum), penicillin (50 U/mL) and streptomycin (50 µg/mL) (Gibco,  
73 US). Centrifugation at 1000g for 10 min were used to obtain promastigotes in their late log  
74 phase (10 million promastigotes/mL). Then, it was washed with phosphate buffer saline  
75 (PBS) at pH 7. Human acute monocytic leukemia cells THP1 was maintained in RPMI  
76 (Gibco, US) media, with added FBS and the antibiotics penicillin and streptomycin. Invitro  
77 conditions changes the promastigotes into amastigotes within the THP1 cells at a ratio of 1:10  
78 (cell: parasite). The amastigotes were isolated by procedures optimized in the laboratory,  
79 following the methods described by Moreno, M.L.V et al., (1998) with some modifications.

### 80 *Accession numbers*

81 The IDs (Identities) and annotations of the novel protein sequences are as follows:

82 (CBZ37742.1 LDBPK\_342650), GeneDB<sup>i</sup> (LdBPK\_301490.1.1: pep), Gene ID: 13392833

### 83 *Prediction of ALSP 3D structure and function through iterative threading assembly* 84 *refinement algorithm (I-TASSER)*

85 ALSP amino acid sequence was uploaded to the I-TASSER server  
86 (<https://zhanglab.ccmb.med.umich.edu/I-TASSER/>) (Yang and Zhang, 2015). A large  
87 ensemble of structural conformations, called decoys is generated by I-TASSER stimulations  
88 for each target. The SPICKER program uses the decoys to select the best five final models  
89 based on pair-wise structure similarity. The confidence score (C-score) is used to determine  
90 the structure quality, which varies between -5 to 2. Higher C-score defines a model as more  
91 significant than a lower one. Template modeling score (TM-score0 and Root Mean Square  
92 Deviation (RMSD) are estimated by confidence score (C-score) and protein length following  
93 the correlation between these parameters.

94 Based on the I- TASSER structure prediction the function of the ALSP has been annotated

95 using COFACTOR and COACH. COFACTOR infers protein functions (ligand-binding sites,  
96 EC and GO) using structure comparison and protein-protein networks. COACH uses a meta-  
97 server approach that combines multiple function annotation results from the COFACTOR,  
98 TM-SITE and S-SITE programs.

### 99 ***Model evaluation***

100 The predicted 3D structure of ALSP was assessed by PROCHECK  
101 (<https://www.ebi.ac.uk/thornton-srv/software/PROCHECK>) and ProQ  
102 (<https://proq.bioinfo.se/cgi-bin/ProQ/ProQ.cgi>) web servers. PROCHECK is used to test the  
103 stereochemical quality and correctness of the 3D protein structure (Laskowski et al., 1993),  
104 and the validation of generated models was further accomplished by ProQ (Wallner and  
105 Elofsson, 2003).

### 106 ***Lipase assay***

107 Triglyceride lipase is an enzyme that hydrolyses triglycerides into glycerol and fatty acid  
108 (Gupta et al., 2003). The enzyme activity of ALSP in whole lysate was checked by Lipase  
109 Assay Kit (REAI GENE, US) in Unit/ $\mu$ g. The Unit/ $\mu$ g (U/ $\mu$ g) is defined as 1 $\mu$ g protein-  
110 producing 1 $\mu$ Mol glycerol/fatty acid in 1min at 37 °C.

111 The 125  $\mu$ M/mL of oleic acid standard solution was diluted to 62.5, 31.25, 15.625, 7.8125  
112 and 3.9  $\mu$ M/mL with anhydrous ethanol to make a standard curve at 710 nm absorbance.

### 113 ***Selection of Antigen as Vaccine Candidate efficiency***

114 The antigenicity of ALSP was checked through ANTIGENPro (Magnan et al, 2010) and  
115 VaxiJen 2.0 online tools (Doytchinova and Flower, 2007).

### 116 ***Cloning the ALSP gene***

117 The ALSP gene (Gene ID: CBZ37742.1) was PCR (polymerase chain reaction) amplified in  
118 50  $\mu$ L reaction volume containing 100 ng of purified genomic DNA of *L. donovani*  
119 promastigotes. 100 pmol forward (EcoRI->5'GT C GAATT CGTATG CAT ATG CGT GTA  
120 CTT GTG CGT 3') and reverse gene-specific primer (XhoI->5'TTCTCGAG TCA GCA  
121 CGG AAA GGA ACG CGA 3'), 200  $\mu$ M dNTP (Deoxynucleotide triphosphates), 3U Taq  
122 DNA polymerase. The fragment was inserted into the pGEX4T2 vector at its multiple cloning  
123 site, utilizing the restriction sites of *EcoRI* and *XhoI*. The pGEX4T2-ALSP hybrid construct  
124 was used to transform the *Escherichia coli* DH5 $\alpha$  and BL21 respectively.

125 ***Confirmatory analysis of Cloning through colony PCR, double digestion of the cloned***  
126 ***Plasmid, and DNA sequencing***

127 ALSP-Forward and Reverse primers were used to do colony PCR with transformed and  
128 untransformed DH5 $\alpha$  and BL21 cells, following the same PCR program. The restriction-  
129 digestion of the ALSP-GST construct was done after isolating the plasmid from the  
130 transformed DH5 $\alpha$  cells using a plasmid isolation mini kit (GCC Biotech). The isolated  
131 plasmid was dissolved in 20  $\mu$ l of Diethyl pyrocarbonate (DEPC)-treated water and used for  
132 Sanger sequencing, performed (Xcelris Labs, Bangalore, India). Nucleotide-nucleotide basic  
133 local alignment search tool (BLASTn) was performed for the chromatogram to check the  
134 identity with the available sequence of Leishmania species in the National Center for  
135 Biotechnology Information (NCBI) database.

136 ***Production of anti ALSP antibody***

137 Antisera were developed against the ALSP by an optimal peptide epitope domain of a protein  
138 (SSPFSSTRSSSSRS –C, the cysteine residue addition at the C terminal end is required for  
139 keyhole limpet hemocyanin (KLH) conjugation, applied by a bioinformatics tool [BioBharati  
140 LifeScience Pvt. Ltd. Kolkata, India]. New -Zealand white rabbit was immunized with this  
141 conjugation. The serum was accumulated from the rabbit in both cases such as before as well  
142 after immunization and it was done up to the 6<sup>th</sup> booster dosage. The final antisera were  
143 obtained at 2 and half months.

144 Antibody titers were obtained by indirect ELISA. 500 pg of strain ALSP per well was applied  
145 to study their titer of different dilutions factor of antisera containing antibody of both the  
146 batches (1:500, 1:1000, 1:2000, 1:5000, 1:10000, 1:20000, 1:400000 dilutions). To determine  
147 the specificity of antibody, the pre-immune sera were diluted very uniformly.

148 ***Affinity-based immune-precipitation assay for the native protein purification***

149  $1 \times 10^6$  cells of promastigote and amastigote were resuspended in 1x PBS (PH-7.4) solution  
150 and for incubation the cells were kept at 4  $^{\circ}$ C for 10 minutes. Followed by rapid freezing –  
151 thawing technique and after centrifugation at 200 g and 100 g the supernatant was collected  
152 in both the cases promastigote and amastigote. Then the collected supernatants were used for  
153 immunoprecipitation with the pre immune sera and antisera of New Zealand White rabbit.  
154 The immunoprecipitation was carried out with Protein A- Sepharose bead, which were added  
155 to the pre-immune sera and antisera in a 1:2 volume ratio and incubated at 4  $^{\circ}$ C overnight  
156 with gentle inversion rotation. Unbounded pre-immune sera and antisera were washed out by

157 using of 1xPBS (PH-7.4). This process was done for repeatedly three times at room  
158 temperature and then centrifuged at 200 g for promastigote and incase of amastigote  
159 centrifuged at 100 g. The soluble supernatants of both forms were added to the specific  
160 antibody loaded Protein A- sepharose column and incubated overnight at 4 °C with gentle  
161 inversion rotation. The unbound protein was removed similarly like before. The bound  
162 protein with antisera and pre-immune sera through Protein A- sepharose bead in both forms  
163 was separated by boiling with sodium dodecyl sulfate polyacrylamide gel electrophoresis  
164 (SDS-PAGE) loading buffer for 15 min at 100 °C and collected by centrifugation. The elutes  
165 were analyzed by immunoblotting after incubation with the same anti-ALSP polyclonal  
166 antibody.

### 167 ***MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization-Time Of Flight)***

168 The protein dialysate was subjected to MALDI-TOF to detects its molecular weight. The  
169 solubilized protein was added on a target MALDI plate matrix using  $\alpha$ -cyano-  
170 hydroxycinnamic acid (CHCA). This was examined by MALDI-TOF mass spectrometer  
171 (Applied Biosystems, USA). The resultant spectra was visualized. The central  
172 instrumentation facility at Council of Scientific & Industrial Research-Indian Institute of  
173 Chemical Biology (CSIR-IICB) Kolkata was used for this study.

### 174 ***Determination of native protein through sequencing***

175 The MALDI-TOF-MS/MS analysis was done using trypsin-digested ALSP to elaborate its  
176 sequence (100 ppm).

### 177 ***Two-step reverse transcription PCR***

178 ALSP transcripts in both forms of *L. donovani* was examined using isolated whole-cell RNA  
179 with TRI Reagent (Sigma T9424). RNA was reversed transcribed to cDNA at 42 °C for 60  
180 min. Forward and reverse ALSP gene-specific primers were used. Polymerase Chain  
181 Reaction (PCR) was used to detect the amplified expression of ALSP.

### 182 ***Fluorescence microscopy***

183 *L. donovani* digenic forms were obtained by centrifugation (4000g for promastigotes and 100  
184 g for amastigotes). The pellets were washed twice with phosphate buffer saline. After fixation  
185 with chilled methanol for 2 min, the cells were treated with permeabilization buffer for 30  
186 sec-1 min. The pellets were rewashed with phosphate buffer saline and conjugated with

187 preimmune sera and immune sera targeted against ALSP (1:25 dilution) in the presence of  
188 blocking agent 3% bovine serum albumin for 45 min. The cells were assessed with  
189 fluorescein isothiocyanate (FITC)-conjugated goat-derived IgG (Thermo Fisher Scientific,  
190 Waltham) (at 1:500 dilution) for 30 min. Cells were viewed after cover slipping with  
191 mounting media plus DAPI and viewed with a fluorescence microscope (Zeiss, UK) at 10 $\times$ .  
192 Pre-immune sera incubation was used as negative controls. Appropriate optical filters were  
193 used for 4',6-diamidino-2-phenylindole (DAPI) ( $\lambda$  = 461 nm) and Fluorescein isothiocyanate  
194 (FITC) ( $\lambda$  = 591 nm) respectively.

### 195 *Localization of ALSP in Leishmania major*

196 The promastigotes of *L. major* were cultivated in a T-25 flask supplemented with M199  
197 media plus 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer at 25  $^{\circ}$ C.  
198 On the other hand, amastigotes of *L. major* were grown in a T-75 flask in RPMI media at 37  
199  $^{\circ}$ C in 5% CO $_2$ . The same protocol for microscopy was followed here as was done for *L.*  
200 *donovani*.

## 201 **RESULTS**

### 202 *Prediction of 3D structure and function of ALSP and evaluation of the Model by* 203 *PROCHECK and ProQ*

204 **Figure 1.a** showed the Helix (H), Coil (C) and Strand (S) regions of the predicted secondary  
205 structure of ALSP and their solvent accessibility.

206 The 3D structure of the ALSP protein was projected by homology modeling with its amino  
207 acid sequence on the I-TASSER. The range of the C-score is -5 to 2, where a model is highly  
208 significant with a magnificent value of c and conversely. C-score of top 5 models were -3.58,  
209 -4.36, -4.77, -4.56, -4.95 respectively. Model 1 contains a higher C-score, as shown here  
210 (**Figure 1.b**).

211 The function of ALSP was determined *in-silico* by COFACTOR and COACH softwares,  
212 derived from the I-TASSER projection. The likely function of ALSP was triglyceride lipase,  
213 (GO: 0004806). The biological process is associated with cytosolic lipid metabolism (GO:  
214 0016042).

215 The lipase enzyme active site of the ALSP may be GAS amino acid' sequence (**Figure 1.c**).

216 Confirmatory study of the ALSP 3D structure was done by construction of Ramachandran



217 plots through PROCHECK. The result revealed that residues of the ALSP model fall within  
218 79.1% and 19.4% in the most favored and additional allowed regions independently, and  
219 there was only 1.5% of residues that fall within disallowed regions (**Figure 1.d**). In broad-  
220 spectrum, a score of about 100% indicates the best stereochemical quality of the model  
221 (Reddy et al., 2006). Consequently, the PROCHECK result proposes that the predicted model  
222 quality of ALSP is satisfactory. The predicted 3D structure quality was also checked via  
223 ProQ and it is evident that the predicted LG score was 2.193, which is greater than 1.5. As  
224 per the ProQ database, if the LG score of a model is than 1.5, then it is a fairly good model.

225 The antigenicity of ALSP was 0.3821 and 0.4294, calculated by using VaxJen and  
226 AntigenPro software.

### 227 ***Pilot study of In-vitro functional analysis of ALSP through Lipase assay***

228 The amino acid sequence of ALSP was examined with the I-TASSER software for predicting  
229 its probable rôle (**Figure 2.a**). Based on the *in-silico* data, the function of ALSP was  
230 examined through *in-vitro* analysis by Lipase assay (**Figure 2.b**). Oleic Acid was used as a  
231 standard solution. ALSP produced glycerol in *L. donovani* amastigote, while the  
232 promastigotes almost did not show any such activity. 2.41 mg/ml crude cell lysate from  
233 amastigotes produced 11.82 µM/mL glycerol. The enzyme activity was calculated for ALSP  
234 in the amastigotes form, and it was estimated to be 48.96 U/µg (**Figure 2.c**).

### 235 ***Overexpression of the leishmanial complete gene (CBZ37742.1) of ALSP and confirmation***

236 The ligated product of pGEX-4T-2 vector and ALSP gene was transferred on LB-AMP plate  
237 with DH5α competent cells (**Figure 3.a**). Thereafter, the cloning of the ALSP gene was  
238 confirmed through colony PCR, restriction digestion, and sequence analysis. The colony PCR  
239 with colony 1 and colony 2 visualized a sharp band for each near 255bp (**Figure 3.b**).  
240 Consequently, those two colonies were used for restriction digestion with *EcoRI* and *XhoI*  
241 restriction enzymes, and the restriction digestion result was exhibited an intense band close  
242 by 255bp and 4970bp for the ALSP gene and pGEX-4T2 vector in respect of 1kb DNA  
243 Marker. The chromatogram confirmed the cloning of ALSP in the pGEX-4T2 vector with  
244 89% identity (**Figure 3.c & 3.d**) in respect to the *L. donovani* database. The target gene was  
245 expressed in *E. coli* BL21 strain and used for protein purification in abundant quantity.

### 246 ***Production of antiserum against epitopic ALSP sequence***

247 The highly probable antigen from KLH conjugated ALSP was used for immunization of NZ

248 White Rabbit. Antibody concentrations were calculated. Affinity purification of antisera was  
249 performed by indirect ELISA. Both batches demonstrated a diminishing titer upon and  
250 increasing dilution. The concentration of pre-immune sera remained insignificant in  
251 comparison with the immunized batches of animals, which implied that the developed  
252 antisera was complementary against the antigen. The Batch 1 showed higher titer than Batch  
253 2 (**Figure 4.a**). Batch 1 was used to purify ALSP-antibody through true affinity purification  
254 (**Figure 4.b**).

255 The specificity was checked using Indirect ELISA (**Figure 4.a and 4.b**) and  
256 Immunoprecipitation (IP) (**Figure 4.e**). The immunoprecipitation was obtained with purified  
257 induced and uninduced ALSP-GST fusion protein. This was pulled down with antisera and  
258 preimmune sera of a NZ White Rabbit, using primary antibody and anti-rabbit-HRP (Horse  
259 Radish Peroxidase) conjugate secondary antibody. A band was seen at 35kDa for purified  
260 ALSP-GST fusion protein (**Figure 4.e**, Lane 4). **Figure 4.c and 4.d** represented the  
261 purification and confirmatory data of ALSP-GST fusion protein.

#### 262 *Digenic Expression of ALSP gene and protein in Leishmania donovani*

263 The gene transcription of ALSP in the promastigote and amastigotes of *L. donovani* were  
264 analyzed by reverse transcription PCR. GAPDH gene (496bp) was used as a positive control  
265 (**Figure 5.a**, L2). PCR for the ALSP gene revealed a band at 255 bp (**Figure 5.A, L4**) for the  
266 amastigotes. No band was seen for the lysate derived from the promastigotes (**Figure 5.A,**  
267 **L3**). This demonstrated that the ALSP mRNA expression was exclusively in the amastigotes.

268 Fluorescence microscopy revealed the expression of ALSP protein in amastigotes but not in  
269 promastigotes. (Figure 5a and b).

#### 270 *Digenic expression of ALSP in L. major amastigotes and promastigotes forms*

271 The transcript level expression of the ALSP gene was checked in both structural forms of *L.*  
272 *major* to confirm its stage specificity. It was done through RTPCR, using complimentary  
273 DNA acquired from the RNA of both the vertebrate and invertebrate forms of *L. major* with  
274 respect to a positive control (GAPDH, 496bp). The PCR amplified products of ALSP with  
275 the gene-specific primers were ran on a 1% agarose gel, which exhibited no band for  
276 amastigotes and promastigotes (**Figure 6.a**, L5 & L6) of *L. major*, but the amastigotes of *L.*  
277 *donovani* showed a clear band about 255bp (**Figure 6.b**, L4) for ALSP.

278 Fluorescence microscopy did not show expression of ALSP in either promastigote or

279 amastigote of *L. major* (Figure 6.b).

### 280 *Purification and sequence analysis of ALSP from Leishmania donovani amastigotes*

281 The antisera against ALSP was used to purify the native protein from the amastigotes' lysate.  
282 Both the antisera and preimmune sera were cross-linked with protein A-Sepharose bead  
283 (Invitrogen-101041). The purification was performed with another negative control, albumin-  
284 like protein. Both the negative controls could not detect the protein. When probed, the lysate  
285 of amastigotes reveals a signal at 10 kDa (Figure 7.a). The precise molecular weight obtained  
286 by MALDI-TOF MS was 10.147 kDa (Figure 7.b). MALDI-TOF-MS-MS analysis showed  
287 the sequence, using the peptide fragments of the trypsin-digested protein (from amastigotes)  
288 (Figure 7.c).

## 289 **DISCUSSION**

290 The results of the current study preliminary suggest that a novel protozoan parasitic protein,  
291 amastin-like surface protein (ALSP), act as a lipase enzyme. The function of the protein was  
292 predicted through *in-silico* analysis by I-TASSER. The in-vitro analysis with lipase assay  
293 showed it produced glycerol in amastigotes. Further, to characterize the protein, it was cloned  
294 in a bacterial system and a polyclonal antibody was produced against the 10kDa protein,  
295 which was present in *L. donovani* amastigote. Immunofluorescence show the expression of  
296 amastin-like surface protein in amastigotes but not in the promastigotes. The protein was  
297 unexpressed in *L. major*.

298 While evaluating the function of our novel protein of interest amastin-like surface protein  
299 (ALSP), the I-TASSER software highly predicted the role of the putative protein as a  
300 triacylglycerol lipase. Closer examination of the peptide sequence shows this protein as  
301 serine-rich, the signature of Class III serine lipases belonging to numerous *Leishmania*  
302 species. In our preliminary experiments, we could demonstrate the lipase activity of the  
303 amastin-like surface protein. This protein did have the spaced trypsin like catalytic triad, Ser-  
304 His-Asp (Brady et al., 1990), though we did not have the scope to examine its secondary  
305 structure in details. Closer examination of the peptide sequence also did not reveal the  
306 commonly described sequence of glycine-x1-serine-x2-glycine (x usually is histidine or  
307 tyrosine), the common catalytic sequence present in a wide variety of lipases. However, a  
308 GAS domain was present in ALSP. GHS domains were present in eleven other putative  
309 lipases of *Leishmania donovani* reported in the GenDB database (data not shown). The

310 amastin-like surface protein (ALSP) does have serine richness and also have histidine and  
311 glycine distribution, as well as terminal serines characteristic of lipases.

312 Lipases are an important class of extracellularly secreted enzymes, contributing to the  
313 exoproteome of multiple *Leishmania* species. Earlier, such a lipase was examined in  
314 *Leishmania major* [Freidlin] (Shakarian et al., 2010). In the current study, either the script or  
315 the mature ALSP protein in *L. major* was not observed. Our cross-examination of multiple  
316 lipases from *L. donovani* from the GenDB database did not show major overlap and sequence  
317 alignment with ALSP, likely supporting our claim that ALSP is a novel lipase of *L. donovani*.  
318 The GenDB database additionally shows lipases present in multiple other species of  
319 *Leishmania* and other kinetoplastids including multiple species of *Trypanosoma*. These  
320 extracellularly secreted lipases are also present in many fungi, as well prokaryotic organisms  
321 like *Yersinia*, *Pseudomonas cepacia* and *Helicobacter pylori* (Slomiany and Slomiany., 1992;  
322 Konig et al., 1996; Straus et al., 1992).

323 What it means to be a functional lipase in *Leishmania* is far from clear but there is few  
324 precedence as to the role of the lipases. These are simple hydrolases generating glycerol and  
325 fatty acids, which are important substrate for metabolic processes. Furthermore, these are  
326 important membrane components and lysis of membrane may be one of first major steps in  
327 insinuation of a deflagellated promastigote into the host phagolysosome to form an  
328 amastigote to accomplish its digenic lifecycle. This however may not be the role for ALSP,  
329 as ALSP expression was seen minimal to non-existent in the promastigote form in the present  
330 study. A previous preliminary study also could not detect any low molecular protein below  
331 20 kDa in *L. donovani* promastigotes (Mitra, 2015) Earlier though it was reported that the  
332 lipase *LdLip3* was present in both the promastigote and the amastigote forms of *L. major*  
333 (Shakarian et al., 2010), where it might contribute to vertebrate host cell entry, as well as  
334 contribute to virulence mechanisms like membrane remodelling of phagolysosome.

335 Parasites rely on a complex system of uptake and synthesis mechanisms to satisfy their lipid  
336 needs. Parasites like *Leishmania* have adopted complex mechanisms of host lipid harvesting  
337 (Hart and Coombs 1982). The glycerol from hydrolysed lipid is transported across to the  
338 parasite from the host cell through aquaporin AQP1-like aquaglyceroporin channels,  
339 contributing to the complex energy metabolism of the parasite (Frezard et al., 2014).  
340 Glycerol-transport proteins have been predicted to be present in *L. donovani* (Ranjan et al.,  
341 2020). Fatty acids derives from the host are transported back to the parasite by complex  
342 mechanisms (Berman et al., 1987, Ramakrishnan et al., 2013). Apart from supporting parasite

343 energy generation, the fatty acids may be importantly involved in neo synthesis of special  
344 membrane lipids like phosphorylceramide (Bouazizi-Ben Messaoud et al., 2017). Recently, a  
345 preliminary study has demonstrated a role for albumin-like protein in uptake of fatty acids by  
346 the intracellular form of *L. donovani* (Laha et al., 2019). Importantly, these channel proteins  
347 are significantly targeted by antimonials, one of the most important chemotherapeutic  
348 avenues for treating advanced leishmanial diseases.

349 Though chemotherapy options like antimonials, amphotericin B and miltefosine remain the  
350 main stay for treating visceral leishmaniasis, emerging drug resistance, non-availability of  
351 drugs and toxicity remain major obstacles in obtaining complete remission and significantly  
352 contributes to sustained mortality of visceral leishmaniasis. Thus, attempts for developing  
353 vaccines have been aimed.

354 ALSP does not have KDEL sequence, making it unlikely to dock to a cell membrane or an  
355 organelle membrane and shall function as an extracellularly secreted lipase. Normally, lipases  
356 are relatively bulky protein with approximate molecular weight of 60 kDa (Cygler et al.,  
357 1993). The predicted molecular weight of the putative lipases of *L. donovani* were around 70  
358 kDa (As seen in UniProt). *LdLip3* molecular weight is 33kDa. Recombinant *Leishmania*  
359 antigens (single peptides/polypeptides) were used to produce second-generation vaccines.  
360 Among different trials, promising results in phase I were shown by GLA-SE adjuvant tagged  
361 LEISH-F3, a multicomponent vaccine, to produce immune response in healthy subjects  
362 (Coler et al., 2015). The molecular weight examination of ALSP revealed a rather relatively  
363 small protein of 10kDa. This makes ALSP an important target as a peptide vaccine  
364 component. Preliminary examination with VaxiJen v2.0 and ANTIGENPro shows the  
365 immunoinformatic feasibility of eliciting cell-based immunity against this peptide target. Our  
366 cloning studies reveal the potential of generating the ALSP protein in large quantities in vitro.  
367 This remains our goals for future studies. Cumulatively, the results of the present study show  
368 that the novel 10kDa ALSP supports *Leishmania donovani* parasitism by its lipolytic activity  
369 in the amastigote form.

370 Because *Leishmania* are obligate parasites, they must procure macromolecules like glycerol  
371 and fatty acids to facilitate their opportunistic survival. Previous studies have shown the  
372 preference of amastigotes in using fatty acids as their carbon source via beta oxidation, apart  
373 from utilizing glucose and proline (Tielens and van Hellemond., 2009; McConville et al.,  
374 2007, Berman., 1987; Hart and Coombs., 1982;). *LdLip3* was shown to be active in both  
375 promastigote and amastigote of *L. donovani* (Shakarian et al., 2010), whereas ALSP activity

376 was negligible in promastigotes of *L. donovani*. ALSP may facilitate the survival of the  
377 parasite by remodelling of the phagolysosome membrane and may induce tissue  
378 inflammation when secreted extracellularly in the human host. Earlier studies have shown  
379 that lipase precursor-like protein confers the oral drug alkylphosphocholine miltefosine (but  
380 not sodium antimony gluconate and amphotericin B) resistance in *L. donovani* by enhancing  
381 macrophage infectivity and increasing IL-10/TNF $\alpha$  ratio (Deep et al., 2018). The solitary  
382 expression of ALSP in amastigotes rather than promastigotes is an exceptional phenomenon,  
383 as only a percentage of proteins are differentially expressed between these morphological  
384 forms. For most part, all proteins are constitutively expressed in both promastigotes and  
385 amastigotes, making it non-selective for the parasite to survive in the invertebrate and human  
386 host (Leifso et al., 2007; Ranjan et al., 2020). Additionally, bioinformatics prediction and the  
387 current study indicates differential expression of ALSP in different species of *Leishmania*  
388 (*donovani* vs. *major*), which also is an intriguing observation.

389 Surprisingly, there is significant overlap between diverse lipases and esterase enzymes  
390 acetylcholine esterase, carboxylesterase and cholesterol esterase (Cygler et al., 1993). Though  
391 the geometry of the active site varies, as also seen with ALSP, there is overlap between these  
392 classes of enzymes. The nomenclature of amastin-like surface protein (ALSP) does not  
393 suggest similarity with amastin proteins, a significant class of surface proteins widely  
394 expressed in all leishmanial species, *Trypanosoma brucei*, responsible for sleeping sickness  
395 and *Trypanosoma cruzi*, the inducer of Chagas disease. Preliminary sequence alignment did  
396 not show overlap with alpha, beta, gamma or delta amastins (data not shown). Though  
397 amastin proteins are such widely distributed, detailed investigation into the function of  
398 amastins are only scant. Secondary structure comparison of amastins has shown its similarity  
399 to claudins, important cell-cell junction proteins (Jackson. 2009). Preliminary reports suggest  
400 that the amastigote form of *T. cruzi* develop cell synapses before the insinuation in the  
401 secondary host cell (Bonfim-Melo et al., 2018). Whether ALSP performs such roles remains  
402 unresolved in the current study. Intriguingly, lipases are related to some cell adhesion  
403 proteins like *Drosophila* neurotactin (de la Escalera et al., 1990).

404 Advanced leishmanial disease often present with bleeding diathesis, making it difficult to  
405 obtain tissue biopsies for establishing diagnosis. Examination of ALSP in the peripheral  
406 blood may aid as a diagnostic tool under such circumstances. Though initial vaccination  
407 strategies have not received robust outcomes, it may be appreciated that efforts to develop  
408 new vaccines are critical. HIV-leishmanial coinfections are important emerging infections

409 across the globe in both rural and urban areas. These important theranostic implications  
410 elevate the significance of further examining the novel protein ALSP in future studies.

411

#### 412 **Conflict of interest**

413 The authors declare that there is no conflict of interest regarding scientific or financial matter.

414

#### 415 **Author Contributions**

416 BB, Performed majority of experiments drafted first version of manuscript; BL, coordinated  
417 MALDI-TOF experiments; AC, reviewed literature, interpreted data, drafted introduction and  
418 discussion; MG, Conceptualized the study, obtained funding, supervised experiments,  
419 coordinated drafting of manuscript.

#### 420 **FUNDING**

421 Ministry of Human Resource Development, Government of India and DST-FIST are being  
422 acknowledge for the fund support.

423

#### 424 **Acknowledgment**

425 A preliminary version of the manuscript was submitted in the BioRxiv repository  
426 (<https://doi.org/10.1101/2020.07.23.218107>). The authors wish to thank Sayan Biswas and  
427 Pratyay Sengupta for help during preparation of the manuscript.

428

#### 429 **References**

430

431 1. Leifso, K., Cohen-Freue, G., Dogra, N., Murray, A., McMaster, W. (2007). Robert.  
432 Genomic and proteomic expression analysis of Leishmania promastigote and  
433 amastigote life stages: The Leishmania genome is constitutively expressed. *Molecular  
434 and Biochemical Parasitology*. 152(1), 35-46.

435

436 2. Pulvertaft, R.J.V., Hoyle, G. (1960). Stages in the life-cycle of Leishmania  
437 donovani. *Transactions of the Royal Society of Tropical Medicine and Hygiene*.  
438 54(2), 191-196.

439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470

3. Alvar, J., Vélez, ID., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., den Boer, M., WHO Leishmaniasis Control Team. (2012). Leishmaniasis worldwide and global estimates of its incidence. *PloS One*. 7(5), e35671.
4. Sundar, S., Agarwal, D. (2016). *A Therapeutic Strategy for Treating Visceral Leishmaniasis in Regions with Drug Resistance*. Springer International Publishing. 53-66.
5. Ghosh, M., Bandyopadhyay, S. (2003). Present status of antileishmanial vaccines. *Mol Cell Biochem.* 253(1-2), 199-205.
6. Zutshi, S., Kuma,r S., Chauhan, P., Bansode, Y., Nair, A., Roy, S., Sarkar, A., Saha, B. (2019). Anti-Leishmanial Vaccines: Assumptions, Approaches, and Annulments. *Vaccines (Basel)*. 7(4), 156.
7. Aslett, M., Aurrecochea, C., Berriman M., Brestelli, J., Brunk, B.P., Carrington, M., et al. (2010). a functional genomic resource for the Trypanosomatidae. *Nucleic Acids Res.* 38(suppl\_1), D457-D462.
8. Sengodan, S.K., Gokulasuriyan, R.K., Ghosh, M. (2014). Comparative in-silico genome analysis of *Leishmania (Leishmania) donovani*: a step towards its species specificity. *Meta Gene*. 2, 782-798.
9. Stober, C.B., Lange, U.G., Roberts, M.T.M., Gilmartin, B., Francis, R., Almeida, R., Peacock, C.S., McCann, S., Blackwell, J.M. (2006). From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine *Leishmania major* infection. *Vaccine*. 24(14), 2602-2616.
10. Rafati, S., Hassani, N., Taslimi, Y., Movassagh, H., Rochette, A., Papadopoulou, B. (2006). Amastin peptide-binding antibodies as biomarkers of active human visceral



- 471 leishmaniasis. *Clinical and Vaccine Immunology*. 13(10), 1104–1110.
- 472
- 473 11. Khan, M.A.A., Jenifar, Q.A., Khaledul, F., Rajashree, C., Prakash, G., Faria, H., et al.
- 474 (2020). An immunoinformatic approach driven by experimental proteomics: in silico
- 475 design of a subunit candidate vaccine targeting secretory proteins of *Leishmania*
- 476 *donovani* amastigotes. *Parasites & Vectors*. 13, 196.
- 477
- 478 12. Rochette, A., McNicoll, F., Girard, J., Breton, M., Leblanc, É., Bergeron, M.G.,
- 479 Papadopoulou, B. (2005). Characterization and developmental gene regulation of a
- 480 large gene family encoding amastin surface proteins in *Leishmania* spp. *Mol Biochem*
- 481 *Parasit*. 140(2), 205-220.
- 482
- 483 13. de Paiva, R.M.C., Grazielle-Silva, V., Cardoso, M.S., Nakagaki, B.N., Mendonça-
- 484 Neto, R.P, Canavaci, A.M.C., et al. (2015). Amastin Knockdown in *Leishmania*
- 485 *braziliensis* Affects Parasite-Macrophage Interaction and Results in Impaired
- 486 Viability of Intracellular Amastigotes. *PLoS Pathogens*. 11(12), e1005296.
- 487
- 488 14. Wassef, M.K., Fioretti T.B., Dwyer, D.M. (1985). Lipid analyses of isolated surface
- 489 membranes of *Leishmania donovani* promastigotes. *Lipids*. 20(2), 108-15.
- 490
- 491 15. Bouazizi-Ben Messaoud, H., Guichard, M., Lawton, P., Delton, I., Azzouz-Maache,
- 492 S. (2017). Changes in Lipid and Fatty Acid Composition During Intramacrophagic
- 493 Transformation of *Leishmania donovani* Complex Promastigotes into Amastigotes.
- 494 *Lipids*. 52(5), 433-441.
- 495
- 496 16. Rabhi, I., Rabhi, S., Ben-Othman, R., Rasche, A., Daskalaki, A., Trentin, B., et al.
- 497 (2012). Transcriptomic signature of *Leishmania* infected mice macrophages: a
- 498 metabolic point of view. *PLoS Negl Trop Dis*. 6(8), e1763.
- 499
- 500 17. O'Neal, A.J., Butler, L.R., Rolandelli, A., Gilk, S.D., Pedra, J.H. (2020). Lipid
- 501 hijacking: a unifying theme in vector-borne diseases. *Elife*. 9, e61675.
- 502
- 503 18. Ramakrishnan, S., Serricchio, M., Striepen, B., Bütikofer, P. (2013). Lipid synthesis

- 504 in protozoan parasites: a comparison between kinetoplastids and apicomplexans. *Prog*  
505 *Lipid Res.* 52(4), 488-512.  
506
- 507 19. Biagiotti, M., Dominguez, S., Yamout, N., Zufferey, R. (2017). Lipidomics and anti-  
508 trypanosomatid chemotherapy. *Clin Transl Med.* 6(1), 27.  
509
- 510 20. Beach, D.H., Holz, G.G. Jr., Anekwe, G.E. (1979) Lipids of *Leishmania*  
511 promastigotes. *J Parasitol.* 65(2), 201-16.  
512
- 513 21. Moreno, M.L.V., Meirelles, M.N.L. (1998). In vitro method for isolation of  
514 amastigote forms of *Leishmania amazonensis* from J774G8 macrophage induced by  
515 temperature shifting. *Memórias do Instituto Oswaldo Cruz.* 93(1), 99–102.  
516
- 517 22. J, Yang., Y, Zhang. (2015). I-TASSER server: new development for protein structure  
518 and function predictions. *Nucleic Acids Research.* 43(W1), W174-W181.
- 519 23. Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J.M. (1993).  
520 PROCHECK: A program to check the stereochemical quality of protein structures.  
521 *Journal of Applied Crystallography.* 26(2), 283–291.
- 522 24. Wallner, B., Elofsson, A. (2003). Can correct protein models be identified? *Protein*  
523 *Science.* 12(5), 1073–1086.
- 524 25. Gupta, R., Rathi, P., Gupta, N., Bradoo, S. (2003). Lipase assays for conventional and  
525 molecular screening: an overview. *Biotechnol Appl Biochem.* 37(Pt 1), 63-71.
- 526 26. Magnan, C.N., Zeller, M., Kayala, M.A., Vigil, A., Randall, A., Felgner, P.L., et al.  
527 (2010). High-throughput prediction of protein antigenicity using protein microarray  
528 data. *Bioinformatics.* 26(23), 2936–43.
- 529 27. Doytchinova, I.A., Flower, D.R. (2007). VaxiJen: a server for prediction of protective  
530 antigens, tumour antigens and subunit vaccines. *BMC Bioinformatics.* 8, 4.
- 531 28. Reddy, C.S., Vijayasathy, K., Srinivas, E., Sastry, G.M., Sastry, G.N. (2006).  
532 Homology modeling of membrane proteins: A critical assessment. *Computational*

- 533 Biology and Chemistry. 30(2), 120–126.
- 534
- 535 29. Brady, L., Brzozowski, A.M., Derewenda, Z.S., Dodson, E.J., Dodson, G.G.,  
536 Tolley, S.P., et al. (1990). A serine protease triad forms the catalytic centre of a  
537 triacylglycerol lipase. *Nature*. 343(6260), 767-70.
- 538
- 539 30. Shakarian, A.M., McGugan, G.C., Joshi, M.B., Stromberg, M., Bowers, L., Ganim,  
540 C., Barowski, J., Dwyer, D.M. (2010). Identification, characterization, and expression  
541 of a unique secretory lipase from the human pathogen *Leishmania donovani*.  
542 *Molecular and Cellular Biochemistry*. 341(1-2), 17-31.
- 543
- 544 31. Slomiany, B.L., Slomiany, A. (1992). Mechanism of *Helicobacter pylori*  
545 pathogenesis: focus on mucus. *Journal of Clinical Gastroenterology*. 14(Suppl 1),  
546 S114–S121.
- 547
- 548 32. König, B., Jaeger, K.E., Sage, A.E., Vasil M.L., König, W. (1996). Role of  
549 *Pseudomonas aeruginosa* lipase in inflammatory mediator release from human  
550 inflammatory effector cells (platelets, granulocytes, and monocytes). *Infect Immun*.  
551 64(8), 3252–3258.
- 552
- 553 33. Straus, D.C., Lonon M.K., Hutson, J.C. (1992). Inhibition of rat alveolar macrophage  
554 phagocytic function by a *Pseudomonas cepacia* lipase. *J Med Microbiol*. 37(5), 335–  
555 340.
- 556
- 557 34. Mitra, P. (2015). Pathogenicity of *Leishmania donovani* is associated with the high  
558 expression of a group low molecular weight proteins. *Tropical Parasitology*. 5(2),  
559 2229-5070.
- 560
- 561 35. Hart, D.T., Coombs, G.H. (1982). *Leishmania mexicana*: energy metabolism of  
562 amastigotes and promastigotes. *Exp Parasitol*. 54(3), 397–409.
- 563
- 564

- 565 36. Frézard, F., Monte-Neto, R., Reis, Priscila, G. (2014). Antimony transport  
566 mechanisms in resistant leishmania parasites. *Biophysical Reviews*. 6(1), 119-132.  
567  
568
- 569 37. Ranjan, R., Das, P., Vijayakumar, S. (2020). Differentially modulated proteins  
570 associated with Leishmaniasis—a systematic review of in-vivo and in-vitro studies.  
571 *Molecular Biology Reports*. 47(11), 9159-9178.  
572
- 573 38. Berman, J.D., Gallalee, J.V., Best, J.M., Hill, T. (1987). Uptake, distribution and  
574 oxidation of fatty acids by *Leishmania mexicana* amastigotes. *J Parasitol*. 73(3), 555–  
575 560.  
576
- 577 39. Laha, B., Verma, A.K., Biswas, B., Sengodan, S.K., Rastogi, A., Willard, B.,  
578 Ghosh, M. (2019). Detection and characterization of an albumin-like protein in  
579 *Leishmania donovani*. *Parasitol Res*. 118(5), 1609-1623.  
580
- 581 40. Cygler, M., Schrag, J.D., Sussman, J.L., Harel, M., Silman, I., Gentry, M.K.,  
582 Bhupendra, P. (1993). Relationship between sequence conservation and three-  
583 dimensional structure in a large family of esterases, lipases, and related proteins.  
584 *Protein Science*. 2(3), 366-382.  
585
- 586 41. Coler, R.N., Duthie, M.S., Hofmeyer, K.A., Guderian, J., Jayashankar, L., Vergara,  
587 J., et al. (2015). From mouse to man: safety, immunogenicity and efficacy of a  
588 candidate leishmaniasis vaccine LEISH-F3+GLA-SE. *Clin Transl Immunology*. 4(4),  
589 e35.  
590
- 591 42. Tielens, A.G.M., van Hellemond, J.J. (2009). Surprising variety in energy  
592 metabolism within Trypanosomatidae. *Trends Parasitol*. 25(10), 482–490.  
593
- 594 43. McConville, M., de Souza, D., Saunders, E., Likic, V.A., Naderer, T. (2007). Living  
595 in a phagolysosome; metabolism of *Leishmania* amastigotes. *Trends Parasitol*. 23(8),  
596 368–374.

- 597  
598 44. Deep, K.D., Singh, R., Kulshrestha, A., Wajid, S., Salotra, P. (2018). Lipase  
599 Precursor-Like Protein Promotes Miltefosine Tolerance in *Leishmania donovani* by  
600 Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host  
601 Macrophages. *Antimicrobial Agents and Chemotherapy*. 62(12), e00666-18.  
602  
603 45. Jackson, A.P. (2009). The Evolution of Amastin Surface Glycoproteins in  
604 Trypanosomatid Parasites. *Molecular Biology and Evolution*. 27(1), 33-45.  
605  
606 46. Bonfim-Melo, A., Ferreira, E.R., Florentino, P.T.V., Mortara, R.A. (2018).  
607 Amastigote Synapse: The Tricks of *Trypanosoma cruzi* Extracellular Amastigotes.  
608 *Frontiers in Microbiology*. 27(9), 1341.  
609  
610 47. De la Escalera, S., Bockamp, E.O., Moya, F., Piovant, M., Jiménez, F. (1990).  
611 Characterization and gene cloning of neurotactin, a *Drosophila* transmembrane  
612 protein related to cholinesterases. *The EMBO Journal*. 9(11), 3593-601.  
613  
614  
615  
616

## 617 **Legends**

618  
619 **Figure. 1 Structure prediction and structure-based function annotation of ALSP through**  
620 ***I-TASSER***. (a) Predicted secondary structure and solvent accessibility of ALSP (b) Predicted  
621 best model of ALSP by *I-TASSER* where C-score is -3.58, estimated TM-score  
622 = $0.32\hat{A}\pm 0.11$ , and estimated RMSD-score= $11.6\hat{A}\pm 4.5\tilde{A}$ . (c) Exhibited GAS region of ALSP  
623 from its amino acids sequence (d) Validation of ALSP predicted 3D model through  
624 Ramachandran plot where 79.1% of ALSP residues fall within the most favoured and 19.4%  
625 in the additional allowed regions independently, and only 1.5 % of residues that fall within  
626 disallowed regions

627  
628 **Figure. 2 Function of ALSP as triglyceride lipase.** (a) The function of ALSP predicted  
629 through *in-silico* analysis using its amino acids sequence in *I-TASSER* online tool. It was

630 found to act as a lipase enzyme with other possible roles. (b) Depicts a standard curve  
631 between different concentration of Oleic Acid and Absorbance of Oleic Acid at 710nm. (c)  
632 Lipase activity of ALSP in amastigotes and promastigote forms. It showed 48.96 U/mg  
633 enzyme activity for amastigotes and very minimal for promastigotes (0.009 U/mg).

634

635 **Figure. 3 Confirmation of the cloning in a prokaryotic system with transformed *DH5 $\alpha$***   
636 ***competent cells through colony PCR, restriction digestion, and sequencing analysis.*** (2.a)

637 Transferred ligated pGEX-4T-2 vector and Gene of Interest (ALSP) on LB-AMP plate with  
638 *E.coli* DH5 $\alpha$  competent cells (2.b) Colony PCR of cloned plasmids of colony 1 (Lane 2) and  
639 colony 2 (Lane 3) and diagram of restriction digestion of those cloned plasmids with EcoRI  
640 and XhoI restriction enzymes exhibited an intense band near 255 bp for each colony in  
641 respect of the 1kb DNA ladder at Lane 1. (2.c and 2.d) Chromatogram of pGEX4T2 vector  
642 with the 255bp long ALSP insert and Sequencing analysis of the ALSP gene through  
643 Nucleotide BLAST against Leishmanial gene data bank.

644

645 **Figure 4 Evaluation of polyclonal antibody against *Leishmania donovani* ALSP protein.**

646 (3.a) Binding dynamics of polyclonal antibodies evaluated by indirect ELISA. The titer of  
647 preimmune serum is highlighted by the green and blue traces. The binding strengths of  
648 antisera in batch 1 and batch 2 are projected by red and black traces respectively. (3.b)  
649 Affinity purification of ALSP-antibody from batch 1. (3.c) Purification of ALSP-GST protein  
650 on 15% SDS-PAGE. 10-250 kDa molecular mass Marker (Lane 1). Lane 2 shows purified  
651 BL21 cells with empty vector; Lane 3 shows purified BL21 cells without Construct; Lane 4,  
652 5 and 6: first, second, and third eluates of ALSP-GST. (3.d) Purified ALSP-GST fusion  
653 protein (about 35 kDa) in induced (Lane 2) and uninduced form (Lane 3). Western Blotting  
654 was performed with Anti-GST-tagged antibody. (Lane 1). (3.e) Immunoprecipitation of  
655 ALSP-GST fusion protein. ALSP-GST in induced and uninduced forms pulled down with  
656 antisera/preimmune sera of an NZ White Rabbit by probing customized anti-amastin-like  
657 surface protein antibody and anti-rabbit-horse radish peroxidase conjugated secondary  
658 antibody. Lane 2 and 3: Antisera/preimmune sera with the uninduced fusion protein; Lane 4  
659 and 5: Antisera/preimmune sera with the purified fusion protein; and Lane 1: 10-250 kDa  
660 molecular mass marker.

661

662 **Figure. 5 Digenic expression of ALSP gene and protein in *Leishmania donovani***  
663 ***promastigotes and amastigotes.*** A. Reverse transcription-based amplicon of ALSP  
664 transcripts of *L. donovani*. Lane 1, 1 kb DNA marker; Lane 2, RT-PCR product of total RNA.  
665 GAPDH used as a positive control Lane 3 & 4, RT-PCR amplicons of RNA from both forms  
666 of the parasites respectively. Lane 4 shows a band at 255 bp, while no band was seen in Lane  
667 3; Lane 2 exhibits a dense band near 496 bp. B. ALSP protein localization in promastigote (a)  
668 and amastigote (b), by fluorescence microscopy.

669

670 **Figure. 6 Digenic expression of ALSP gene and protein in *Leishmania major***  
671 ***promastigotes and amastigotes.*** A. RT-based enhancement of ALSP transcripts by total RNA  
672 acquired from both morphological forms of the parasite *L. major*. Lane 1, 1 kb DNA marker;  
673 Lane 2, RT-PCR product of whole-cell RNA of GAPDH, used as a positive control, and Lane  
674 3 & 4, RT-PCR products of whole-cell RNA from both structural forms of *L.*  
675 *donovani* respectively and Lane 5 & Lane 6 contain RT-PCR yields of total-cell RNA of *L.*  
676 *major* in both respective shapes. Lane 4 contains a band near 255 bp; no detection of bands in  
677 Lane 3, Lane 5, and Lane 6; Lane 2 displays a clear band nearby 496 bp. B. Fluorescence  
678 microscopy did not detect ALSP in the promastigotes and amastigotes of *trypan* *L. major*.

679

680 **Figure. 7 Western blot of ALSP expression and determination of molecular weight of**  
681 ***ALSP by MALDI-TOF.*** (a) Western blotting was carried out with antiserum and anti-rabbit  
682 horse radish peroxidase conjugated secondary antibody. Lane 1, molecular mass marker (10-  
683 250 kDa); Lane 2, purified protein expressed in promastigotes, used as negative control; Lane  
684 3, ALSP band at 10 kDa in amastigotes; Lane 4, albumin-like protein expressed in  
685 amastigotes, used as negative control. (b) The M peak at 10.147 kDa revealed the accurate  
686 molecular mass of ALSP by MALDI mass spectrometry. (c) Sequencing of the purified  
687 protein was done by MALDI-TOF-MS-MS analysis after tryptic digestion. The sequencing  
688 data of ALSP after MALDI-TOF-MS-MS analysis showed 100% similarity with leishmanial  
689 amastin-like surface protein (ALSP) when uploaded in the NCBI for BLASTn

**a**


Predicted Secondary Structure

Sequence	MHMRVLVRACTLSRGSPWLSPIPHSPPSALLSSSVAPSR	LPCGSLCCAPPLHLSQHF	GARFRRWGAS	SPFSSTRSSSSSR	SFPC
Prediction	CCCCCCCCCCCCCC	HHHHH	CCCCCCCCCC	HHHHHHHHHHH	CCCCCCCCCCCCCC
Conf. Score	9424314321104688565668999827776334474558766511068235888770787773136898654445655566789				
	H:Helix; S:Strand; C:Coil				

Predicted Solvent Accessibility

Sequence	MHMRVLVRACTLSRGSPWLSPIPHSPPSALLSSSVAPSR	LPCGSLCCAPPLHLSQHF	GARFRRWGAS	SPFSSTRSSSSSR	SFPC
Prediction	742321132132444442244144433432244423444231332013333313531343144234744244445455546248				
	Values range from 0 (buried residue) to 9 (highly exposed residue)				


**b**



**c**

```
>tr|E9BR63|E9BR63_LEIDB Amastin-  
like surface protein, putative  
OS=Leishmania donovani (strain  
BPK282A1) OX=981087  
GN=LDBPK_342650 PE=4 SV=1  
MHMRVLVRACTLSRGSPWLSPIPHSPPSALLSS  
VAPSR LPCGSLCCAPPLHLSQHF GARFRRWGAS  
PFSTRSSSSSRSFPC
```

**d**



6664802\_01.ps



